BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 26378065)

  • 1. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
    Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
    Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
    Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
    BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
    Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
    BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
    Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
    Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value.
    Kwon MJ; Jeon JY; Park HR; Nam ES; Cho SJ; Shin HS; Kwon JH; Kim JS; Han B; Kim DH; Choi YL
    Pancreas; 2015 Apr; 44(3):484-92. PubMed ID: 25513781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
    Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
    Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Will molecular diagnostics become established in pancreatic pathology?].
    Sipos B; Sperveslage J
    Pathologe; 2013 Nov; 34 Suppl 2():214-20. PubMed ID: 24196616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
    Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
    Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
    Yu J; Sadakari Y; Shindo K; Suenaga M; Brant A; Almario JAN; Borges M; Barkley T; Fesharakizadeh S; Ford M; Hruban RH; Shin EJ; Lennon AM; Canto MI; Goggins M
    Gut; 2017 Sep; 66(9):1677-1687. PubMed ID: 27432539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
    Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
    Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.